Today, Greenwich LifeSciences announced that all US sites in its Phase III FLAMINGO-01 trial — which is evaluating GLSI-100, a GP2-based immunotherapy aimed at preventing breast cancer recurrence in HER2-expressing patients — had transitioned to commercially manufactured drug product mid-study, following FDA approval in January 2026. The announcement was framed as a milestone, the kind of operational signal that tells investors the company is preparing for a commercial future. And maybe it is. But behind that framing sits one of the most consequential and underappreciated regulatory maneuvers a sponsor can execute during a pivotal trial: a manufacturing change that introduces new product into an ongoing comparative dataset.

Most observers will read this as good news. Commercial-scale manufacturing means Greenwich is betting on approval. But the question regulators will ask is not whether the company is optimistic — it is whether the new material is demonstrably equivalent to what participants received before the switch, and whether the trial’s data integrity can survive that transition intact.

Both answers require evidence. The announcement does not provide it.

The Comparability Burden the Press Release Skips

FDA’s guidance on comparability protocols for biologics, first codified under 21 CFR 601.12 and elaborated in the agency’s 2003 draft guidance on comparability protocols, is unambiguous on this point: any manufacturing change that could affect the identity, strength, quality, purity, or potency of a biological product requires a comparability assessment before that material enters patients. The regulatory standard is not sameness — it is demonstrated comparability, supported by analytical, functional, and where necessary, clinical data. For a peptide-based immunotherapy like GP2, where immunogenicity profiles and lot-to-lot consistency directly affect the immune response being measured as the primary endpoint, the analytical bar is not ceremonial. It is existential to the trial’s interpretability.

Greenwich LifeSciences has not publicly disclosed whether a comparability protocol was submitted to FDA, what analytical methods were used to bridge clinical-grade to commercial-grade GP2, or whether the agency reviewed and accepted the comparability data before patients received the new material. Those disclosures may exist in regulatory filings the public cannot see. But their absence from the announcement is notable — and for sponsors watching this case study, instructive.

The deeper concern is what a mid-trial manufacturing change does to a Phase III dataset. FLAMINGO-01 is enrolling patients with HER2-positive breast cancer across multiple sites, measuring recurrence prevention over time. If patients enrolled in the early cohorts received clinical-grade GP2 and later cohorts receive commercially manufactured GP2, the trial has effectively introduced a manufacturing-era variable into a dataset that must ultimately support a Biologics License Application. FDA reviewers will ask whether immune response characteristics — antibody titers, T-cell activation profiles — are consistent across the manufacturing transition. If they are not, or if the comparability data is thin, the agency has grounds to request additional bridging studies or, in a worst-case scenario, question whether the pivotal dataset is interpretable as a single unified trial.

Precedent Shows This Risk Is Not Theoretical

This is not a hypothetical concern invented for editorial effect. The FDA’s comparability protocol guidance details the comprehensive nature of these assessments. The tolerance for unexplained variation in a pivotal trial context is narrow.

The precedent that should be on every sponsor’s radar here is the 2021 Complete Response Letter (CRL) received by Provention Bio for teplizumab. Despite the drug showing clear clinical efficacy and receiving a positive recommendation from an FDA Advisory Committee, the agency issued a CRL specifically because the company could not demonstrate a comparability bridge between its clinical-scale material and its new commercial-scale drug product.

In the CRL, the FDA was explicit:

As PK remains the primary endpoint for demonstration of comparability between the two products, you will need to establish PK comparability appropriately… or provide other data that adequately justify why PK comparability is not necessary.

The underlying lesson is the same: the FDA’s  CMC reviewers operate on a separate—and sometimes more exacting—timeline than clinical reviewers. A pivotal trial can be data-complete and statistically significant, yet still fail at the finish line because the sponsor cannot prove the commercial-era drug is analytically identical to the “clinical-era” drug that generated the efficacy data.

For a peptide-based immunotherapy like GP2, where the “primary endpoint for comparability” will likely be complex immunogenicity or T-cell activation profiles rather than simple PK, a mid-trial manufacturing transition fragments the CMC narrative at precisely the moment it should be consolidating. The FDA rejected the teplizumab filing for exactly this type of manufacturing-era variable, demonstrating that “clinical success” does not guarantee “regulatory approval” if the drug product itself has evolved during the study.

FDA’s guidance on adaptive trial design — the 2019 guidance on adaptive designs for clinical trials of drugs and biologics — is explicit that changes to trial conduct during the study must be pre-specified or prospectively managed to prevent operational bias. A manufacturing transition is not an adaptive design element, but the underlying principle applies with equal force: unplanned mid-trial changes that alter what patients receive create interpretation burdens that prospective protocol amendments and comparability data can mitigate, but cannot eliminate retroactively. The key word is prospective. If Greenwich’s comparability assessment was completed and accepted by FDA before the first commercially manufactured dose was administered, the regulatory pathway is defensible. If the sequence ran in the other direction, the risk profile changes substantially.

What FLAMINGO-01 Needs to Demonstrate — Now

Greenwich LifeSciences is a clinical-stage company with a market capitalization that, as of March 16, 2026, is $0.37 billion. This reflects the binary nature of a pivotal FLAMINGO-01 trial. There is no diversified pipeline absorbing the risk here, though Greenwich LifeSciences plans to diversify its pipeline, by characterizing GP2 specific T cells. That commercial pressure may be exactly why the manufacturing transition announcement was framed as a milestone rather than a regulatory event — but that framing does not change what the FDA will require when the BLA package arrives.

The protocol amendment question is equally pressing. FDA’s regulations under 21 CFR 312.30 require sponsors to submit protocol amendments when changes might affect the safety of subjects, alter the scientific soundness of the study, or affect the acceptability of the data. A manufacturing change that introduces new material into a pivotal immunotherapy trial plausibly touches all three of those triggers. If FLAMINGO-01’s protocol was amended to incorporate the manufacturing transition — specifying the change, the comparability criteria, and the lot traceability requirements — that amendment should be part of the public record or at minimum disclosed to investigators through a protocol deviation management framework. If it was not, the trial’s GCP compliance posture warrants scrutiny.

There is a version of this story where Greenwich has done everything right: they filed a comparability protocol, received FDA feedback, executed a formal protocol amendment, trained sites on lot traceability, and stratified their database to flag the manufacturing transition as a covariate in their statistical analysis plan. That version exists. But the announcement does not describe it. For a company whose entire enterprise value is tied to the regulatory acceptability of FLAMINGO-01’s data package, communicating the regulatory architecture around this transition is not optional disclosure — it is the difference between a data package the FDA reads as methodologically sound and one that generates a 74-day Complete Response cycle.

The broader lesson here extends beyond Greenwich. Mid-trial manufacturing transitions are not unusual in Phase III oncology immunotherapy programs — scale-up pressure, commercial partnerships, and timeline optimization all create incentives to move to commercial-grade material before the trial closes. But the clinical operations community has not developed a visible, standardized public disclosure framework for how sponsors are managing the comparability bridge when they do. FDA’s guidance on comparability protocols for human drugs and biologics, the May 2003 CMC guidance for INDs for Phase 2 and Phase 3 studies, and 21 CFR 601.12 together form a regulatory scaffold that is robust on paper. Whether it is being applied with the rigor pivotal trial data demands is a question that only the BLA review will answer — by which point, correcting the record is no longer an option.

FLAMINGO-01 may produce compelling efficacy data in HER2-expressing breast cancer patients. GP2 may prove to be a genuinely effective recurrence-prevention immunotherapy. But if the manufacturing transition was not managed with the same evidentiary discipline the FDA applies to the clinical endpoints themselves, none of that will matter when the BLA reviewer opens the CMC module. The agency does not grade on optimism.

Website |  + posts

Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.